These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12928047)

  • 1. Combination of serum markers related to several mechanisms in Alzheimer's disease.
    Teunissen CE; Lütjohann D; von Bergmann K; Verhey F; Vreeling F; Wauters A; Bosmans E; Bosma H; van Boxtel MP; Maes M; Delanghe J; Blom HJ; Verbeek MM; Rieckmann P; De Bruijn C; Steinbusch HW; de Vente J
    Neurobiol Aging; 2003 Nov; 24(7):893-902. PubMed ID: 12928047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease.
    Pirttila T; Mehta PD; Frey H; Wisniewski HM
    Neurobiol Aging; 1994; 15(3):313-7. PubMed ID: 7936055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum alpha 1-antichymotrypsin is not a useful marker for Alzheimer's disease or dementia in Parkinson's disease.
    Kuiper MA; van Kamp GJ; Bergmans PL; Scheltens P; Wolters EC
    J Neural Transm Park Dis Dement Sect; 1993; 6(2):145-9. PubMed ID: 8117411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response.
    Licastro F; Morini MC; Polazzi E; Davis LJ
    J Neuroimmunol; 1995 Mar; 57(1-2):71-5. PubMed ID: 7535791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia.
    Lieberman J; Schleissner L; Tachiki KH; Kling AS
    Neurobiol Aging; 1995; 16(5):747-53. PubMed ID: 8532107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?
    Licastro F; Pedrini S; Caputo L; Annoni G; Davis LJ; Ferri C; Casadei V; Grimaldi LM
    J Neuroimmunol; 2000 Feb; 103(1):97-102. PubMed ID: 10674995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased chemiluminescence response of neutrophils from the peripheral blood of patients with senile dementia of the Alzheimer's type.
    Licastro F; Morini MC; Davis LJ; Malpassi P; Cucinotta D; Parente R; Melotti C; Savorani G
    J Neuroimmunol; 1994 Apr; 51(1):21-6. PubMed ID: 8157733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults.
    Mangialasche F; Solomon A; Kåreholt I; Hooshmand B; Cecchetti R; Fratiglioni L; Soininen H; Laatikainen T; Mecocci P; Kivipelto M
    Exp Gerontol; 2013 Dec; 48(12):1428-35. PubMed ID: 24113154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between serum alpha 1-antichymotrypsin and Alzheimer's disease.
    Hinds TR; Kukull WA; Van Belle G; Schellenberg GD; Villacres EC; Larson EB
    Neurobiol Aging; 1994; 15(1):21-7. PubMed ID: 8159260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease.
    Dursun E; Gezen-Ak D; Hanağası H; Bilgiç B; Lohmann E; Ertan S; Atasoy İL; Alaylıoğlu M; Araz ÖS; Önal B; Gündüz A; Apaydın H; Kızıltan G; Ulutin T; Gürvit H; Yılmazer S
    J Neuroimmunol; 2015 Jun; 283():50-7. PubMed ID: 26004156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monomeric and polymeric forms of alpha-1 antichymotrypsin in sera from patients with probable late onset Alzheimer's disease.
    Licastro F; Sirri V; Trerè D; Davis LJ
    Dement Geriatr Cogn Disord; 1997; 8(6):337-42. PubMed ID: 9370085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood levels of alpha-1-antichymotrypsin and risk factors for Alzheimer's disease: effects of gender and apolipoprotein E genotype.
    Licastro F; Masliah E; Pedrini S; Thal LJ
    Dement Geriatr Cogn Disord; 2000; 11(1):25-8. PubMed ID: 10629358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk.
    Licastro F; Pedrini S; Ferri C; Casadei V; Govoni M; Pession A; Sciacca FL; Veglia F; Annoni G; Bonafè M; Olivieri F; Franceschi C; Grimaldi LM
    Ann Neurol; 2000 Sep; 48(3):388-91. PubMed ID: 10976648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated alpha 1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients.
    Altstiel LD; Lawlor B; Mohs R; Schmeidler J; Dalton A; Mehta P; Davis K
    Dementia; 1995; 6(1):17-20. PubMed ID: 7728215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aging and Alzheimer's disease: protease inhibitors in cerebrospinal fluid.
    Delamarche C; Berger F; Gallard L; Pouplard-Barthelaix A
    Neurobiol Aging; 1991; 12(1):71-4. PubMed ID: 2002886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease.
    Sun YX; Minthon L; Wallmark A; Warkentin S; Blennow K; Janciauskiene S
    Dement Geriatr Cogn Disord; 2003; 16(3):136-44. PubMed ID: 12826739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 24S-hydroxycholesterol: a marker of brain cholesterol metabolism.
    Lütjohann D; von Bergmann K
    Pharmacopsychiatry; 2003 Sep; 36 Suppl 2():S102-6. PubMed ID: 14574622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma levels of alpha-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: a potential therapeutic target.
    Porcellini E; Davis EJ; Chiappelli M; Ianni E; Di Stefano G; Forti P; Ravaglia G; Licastro F
    Curr Pharm Des; 2008; 14(26):2659-64. PubMed ID: 18991685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease.
    Angelis P; Scharf S; Mander A; Vajda F; Christophidis N
    Neurosci Lett; 1998 Mar; 244(2):106-8. PubMed ID: 9572596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum markers in relation to cognitive functioning in an aging population: results of the Maastricht Aging Study (MAAS)].
    Teunissen CE; van Boxtel MP; Bosma H; Jolles J; Lütjohann D; von Bergmann K; Wauters A; Bosmans E; Maes M; Delanghe J; De Bruijn C; Steinbusch HW; Blom HJ; de Vente J
    Tijdschr Gerontol Geriatr; 2003 Feb; 34(1):6-12. PubMed ID: 12629905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.